glp-1/gip/glucagon triple agonist name Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Schematic illustration of monoagonists, dual

Step 4: If your journey continues past 12 weeks, 30-minute check in every four-weeks as needed until we reach your goal

Authors relationships and activities The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work

Benefits of GLP-1 therapy: Non-invasive Average weight loss: 1020% (depending on medication) Improved blood sugar control, lower cholesterol, and reduced cardiovascular risk Some patients achieve remission of type 2 diabetes Common side effects: Nausea, vomiting, diarrhea, constipation Rare gallbladder or pancreas-related issues Possible muscle loss if weight loss happens too quickly without proper exercise Considerations GLP-1 medications require continuous use to maintain weight loss

Mild appetite changes, nothing dramatic

One study (SURPASS-2) specifically compared Mounjaro 5 mg, 10 mg, and 15 mg to low-dose semaglutide (1 mg) in people with type 2 diabetes

The analogs of 7 created in this manner were tested for DPP-8 and DPP-9 activity, as well as for activity against DPP-4 and DPP-2